What is Corcept Therapeutics Inc's earnings per share (EPS)?

Corcept Therapeutics Inc (CORT) reported diluted earnings per share of $0.82 for fiscal year 2025. This represents a -33.3% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Corcept Therapeutics Inc Financials

CORT

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2025 Currency USD FYE December

This page shows Corcept Therapeutics Inc (CORT) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 26 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 60/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

Corcept Therapeutics Inc has an operating margin of 5.9%, meaning the company retains $6 of operating profit per $100 of revenue. This results in a moderate score of 35/100, indicating healthy but not exceptional operating efficiency. This is down from 20.3% the prior year.

Growth

Corcept Therapeutics Inc's revenue grew 12.8% year-over-year to $761.4M, a solid pace of expansion. This earns a growth score of 55/100.

Leverage

Corcept Therapeutics Inc carries a low D/E ratio of 0.29, meaning only $0.29 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 96/100, indicating a strong balance sheet with room for future borrowing.

Liquidity

Corcept Therapeutics Inc's current ratio of 2.92 indicates adequate short-term liquidity, earning a score of 56/100. The company can meet its near-term obligations, though with limited headroom.

Cash Flow

Corcept Therapeutics Inc converts 18.6% of revenue into free cash flow ($141.8M). This strong cash generation earns a score of 72/100.

Returns

Corcept Therapeutics Inc's ROE of 15.4% shows moderate profitability relative to equity, earning a score of 45/100. This is down from 20.8% the prior year.

Altman Z-Score Safe

16.98

Corcept Therapeutics Inc scores 16.98, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($4.5B) relative to total liabilities ($188.8M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.

Piotroski F-Score Neutral

4/9

Corcept Therapeutics Inc passes 4 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Cash-Backed

1.42x

For every $1 of reported earnings, Corcept Therapeutics Inc generates $1.42 in operating cash flow ($142.0M OCF vs $99.7M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$761.4M

YoY+12.8%

5Y CAGR+16.6%

10Y CAGR+31.2%

Corcept Therapeutics Inc generated $761.4M in revenue in fiscal year 2025. This represents an increase of 12.8% from the prior year.

EBITDA

$45.9M

YoY-66.6%

5Y CAGR-18.6%

Corcept Therapeutics Inc's EBITDA was $45.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 66.6% from the prior year.

Net Income

$99.7M

YoY-29.4%

5Y CAGR-1.2%

Corcept Therapeutics Inc reported $99.7M in net income in fiscal year 2025. This represents a decrease of 29.4% from the prior year.

EPS (Diluted)

$0.82

YoY-33.3%

5Y CAGR-0.7%

Corcept Therapeutics Inc earned $0.82 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 33.3% from the prior year.

Cash & Balance Sheet

Free Cash Flow

$141.8M

YoY-27.7%

5Y CAGR-1.2%

10Y CAGR+46.5%

Corcept Therapeutics Inc generated $141.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 27.7% from the prior year.

Cash & Debt

$120.5M

YoY-5.6%

5Y CAGR+9.6%

10Y CAGR+11.5%

Corcept Therapeutics Inc held $120.5M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

106M

YoY+0.8%

5Y CAGR-1.9%

10Y CAGR-0.3%

Corcept Therapeutics Inc had 106M shares outstanding in fiscal year 2025. This represents an increase of 0.8% from the prior year.

Margins & Returns

Gross Margin

98.3%

YoY-0.1pp

5Y CAGR-0.1pp

10Y CAGR+1.0pp

Corcept Therapeutics Inc's gross margin was 98.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 0.1 percentage points from the prior year.

Operating Margin

5.9%

YoY-14.4pp

5Y CAGR-30.3pp

10Y CAGR+12.7pp

Corcept Therapeutics Inc's operating margin was 5.9% in fiscal year 2025, reflecting core business profitability. This is down 14.4 percentage points from the prior year.

Net Margin

13.1%

YoY-7.8pp

5Y CAGR-16.9pp

10Y CAGR+25.8pp

Corcept Therapeutics Inc's net profit margin was 13.1% in fiscal year 2025, showing the share of revenue converted to profit. This is down 7.8 percentage points from the prior year.

Return on Equity

15.4%

YoY-5.4pp

5Y CAGR-4.9pp

10Y CAGR+50.0pp

Corcept Therapeutics Inc's ROE was 15.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 5.4 percentage points from the prior year.

Capital Allocation

R&D Spending

$254.9M

YoY+3.2%

5Y CAGR+17.3%

10Y CAGR+32.4%

Corcept Therapeutics Inc invested $254.9M in research and development in fiscal year 2025. This represents an increase of 3.2% from the prior year.

Share Buybacks

$172.9M

YoY+1003.9%

5Y CAGR+77.0%

Corcept Therapeutics Inc spent $172.9M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 1003.9% from the prior year.

Capital Expenditures

$211K

YoY-90.3%

5Y CAGR-29.8%

10Y CAGR+28.6%

Corcept Therapeutics Inc invested $211K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 90.3% from the prior year.

CORT Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$761.4M+12.8%	$675.0M+39.9%	$482.4M+20.0%	$401.9M+9.8%	$366.0M+3.4%	$353.9M
Cost of Revenue	$13.0M+19.3%	$10.9M+67.9%	$6.5M+20.4%	$5.4M+2.0%	$5.3M-5.4%	$5.6M
Gross Profit	$748.4M+12.7%	$664.2M+39.6%	$475.9M+20.0%	$396.5M+9.9%	$360.7M+3.6%	$348.3M
R&D Expenses	$254.9M+3.2%	$246.9M+33.9%	$184.4M+40.7%	$131.0M+15.0%	$113.9M-0.8%	$114.8M
SG&A Expenses	$448.7M+60.1%	$280.3M+52.1%	$184.3M+20.6%	$152.8M+24.9%	$122.4M+16.2%	$105.3M
Operating Income	$44.8M-67.3%	$137.0M+27.7%	$107.3M-4.8%	$112.6M-9.5%	$124.5M-2.9%	$128.2M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$33.2M-263.6%	$20.3M+10.1%	$18.4M+24.7%	$14.8M+18.2%	$12.5M-51.2%	$25.6M
Net Income	$99.7M-29.4%	$141.2M+33.0%	$106.1M+4.7%	$101.4M-9.9%	$112.5M+6.1%	$106.0M
EPS (Diluted)	$0.82-33.3%	$1.23+30.9%	$0.94+8.0%	$0.87-2.2%	$0.89+4.7%	$0.85

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Revenue	$202.1M-2.7%	$207.6M+6.8%	$194.4M+23.7%	$157.2M-13.6%	$181.9M-0.4%	$182.5M+11.4%	$163.8M+11.6%	$146.8M
Cost of Revenue	$2.5M-44.6%	$4.6M+33.9%	$3.4M+42.9%	$2.4M-18.7%	$3.0M+3.1%	$2.9M+13.6%	$2.5M-0.4%	$2.5M
Gross Profit	$199.6M-1.7%	$203.0M+6.3%	$191.0M+23.4%	$154.8M-13.5%	$178.9M-0.4%	$179.7M+11.4%	$161.3M+11.8%	$144.3M
R&D Expenses	$64.9M-5.8%	$68.8M+13.8%	$60.5M-0.4%	$60.7M-13.6%	$70.3M+18.5%	$59.3M+1.0%	$58.7M+0.4%	$58.5M
SG&A Expenses	$130.2M+5.0%	$124.0M+19.4%	$103.9M+14.5%	$90.7M+8.7%	$83.4M+13.1%	$73.7M+10.2%	$66.9M+19.0%	$56.3M
Operating Income	$4.5M-56.1%	$10.2M-61.7%	$26.7M+680.9%	$3.4M-86.5%	$25.3M-45.8%	$46.6M+30.9%	$35.6M+20.7%	$29.5M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	-$14.4M-224.9%	-$4.4M-28.0%	-$3.5M+68.4%	-$10.9M-999.5%	$1.2M-78.8%	$5.7M-6.2%	$6.1M-15.5%	$7.2M
Net Income	$24.3M+23.5%	$19.7M-44.0%	$35.1M+71.1%	$20.5M-33.2%	$30.7M-34.9%	$47.2M+33.0%	$35.5M+27.8%	$27.8M
EPS (Diluted)	N/A	$0.16-44.8%	$0.29+70.6%	$0.17	N/A	$0.41+28.1%	$0.32+28.0%	$0.25

CORT Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$836.7M-0.5%	$840.6M+35.2%	$621.5M+6.5%	$583.4M+37.7%	$423.8M-25.9%	$571.7M
Current Assets	$485.5M+2.9%	$471.6M+2.8%	$458.6M-8.1%	$499.3M+87.4%	$266.5M-44.3%	$478.5M
Cash & Equivalents	$120.5M-5.6%	$127.7M-5.8%	$135.6M+104.4%	$66.3M-14.5%	$77.6M+1.9%	$76.2M
Inventory	$12.9M+3.7%	$12.4M+60.6%	$7.7M+26.7%	$6.1M+22.3%	$5.0M+1.6%	$4.9M
Accounts Receivable	$59.8M+10.8%	$54.0M+31.3%	$41.1M+32.4%	$31.1M+12.4%	$27.6M+5.4%	$26.2M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$188.8M+17.3%	$161.0M+40.2%	$114.8M+40.7%	$81.6M+70.2%	$48.0M-0.9%	$48.4M
Current Liabilities	$166.1M+18.0%	$140.8M+34.7%	$104.5M+44.2%	$72.5M+52.5%	$47.5M+0.1%	$47.5M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$647.8M-4.7%	$679.6M+34.1%	$506.7M+1.0%	$501.8M+33.5%	$375.8M-28.2%	$523.3M
Retained Earnings	$643.4M+18.3%	$543.7M+35.1%	$402.5M+35.8%	$296.4M+52.0%	$195.0M+136.5%	$82.5M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Total Assets	$836.7M+1.6%	$823.6M+2.7%	$801.7M-5.3%	$846.5M+0.7%	$840.6M+7.2%	$784.3M+9.8%	$714.6M+8.9%	$655.9M
Current Assets	$485.5M-10.3%	$541.1M+22.1%	$443.1M+1.1%	$438.5M-7.0%	$471.6M+1.0%	$467.0M-16.7%	$560.8M+11.4%	$503.4M
Cash & Equivalents	$120.5M-3.7%	$125.1M+21.8%	$102.7M+14.4%	$89.8M-29.6%	$127.7M-7.0%	$137.3M+6.8%	$128.6M-14.1%	$149.8M
Inventory	$12.9M+4.2%	$12.3M+0.6%	$12.3M-14.6%	$14.4M+15.8%	$12.4M+54.2%	$8.1M-3.6%	$8.3M+16.1%	$7.2M
Accounts Receivable	$59.8M-14.1%	$69.6M+7.8%	$64.6M+4.4%	$61.8M+14.5%	$54.0M-9.6%	$59.7M+10.9%	$53.8M-12.5%	$61.5M
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$188.8M-1.5%	$191.7M+15.5%	$165.9M+1.7%	$163.2M+1.4%	$161.0M+10.7%	$145.4M+22.9%	$118.3M+9.5%	$108.1M
Current Liabilities	$166.1M-3.6%	$172.3M+19.1%	$144.7M+1.1%	$143.1M+1.6%	$140.8M+11.5%	$126.2M+25.3%	$100.8M+3.7%	$97.2M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$647.8M+2.5%	$631.9M-0.6%	$635.8M-7.0%	$683.3M+0.5%	$679.6M+6.4%	$638.8M+7.1%	$596.2M+8.8%	$547.9M
Retained Earnings	$643.4M+3.9%	$619.1M+3.3%	$599.4M+6.2%	$564.3M+3.8%	$543.7M+6.0%	$513.0M+10.1%	$465.8M+8.2%	$430.3M

CORT Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$142.0M-28.4%	$198.3M+56.5%	$126.7M+5.3%	$120.3M-28.3%	$167.9M+10.5%	$152.0M
Capital Expenditures	$211K-90.3%	$2.2M+1462.6%	$139K-66.3%	$413K-11.9%	$469K-62.1%	$1.2M
Free Cash Flow	$141.8M-27.7%	$196.1M+55.0%	$126.5M+5.5%	$119.9M-28.4%	$167.4M+11.1%	$150.7M
Investing Cash Flow	$69.8M+139.3%	-$177.6M-295.4%	$90.9M+179.5%	-$114.3M-184.0%	$136.1M+214.1%	-$119.3M
Financing Cash Flow	-$220.4M-677.3%	-$28.3M+80.9%	-$148.7M-760.5%	-$17.3M+94.3%	-$302.6M-2577.4%	$12.2M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$172.9M+1003.9%	$15.7M	$0	$0	N/A	$9.9M

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Operating Cash Flow	$38.4M-29.4%	$54.5M+24.0%	$43.9M+756.8%	$5.1M-91.5%	$60.1M-18.1%	$73.3M+77.9%	$41.2M+73.4%	$23.8M
Capital Expenditures	$50K	$0-100.0%	$57K-45.2%	$104K-14.0%	$121K-92.6%	$1.6M+293.0%	$416K	$0
Free Cash Flow	$38.4M-29.5%	$54.5M+24.2%	$43.9M+773.4%	$5.0M-91.6%	$59.9M-16.4%	$71.7M+75.8%	$40.8M+71.6%	$23.8M
Investing Cash Flow	-$11.8M-180.9%	$14.6M-79.1%	$70.1M+2311.5%	-$3.2M+95.1%	-$64.4M-46.2%	-$44.0M+26.8%	-$60.2M-567.8%	-$9.0M
Financing Cash Flow	-$31.2M+32.7%	-$46.4M+54.9%	-$102.9M-158.6%	-$39.8M-772.1%	-$4.6M+78.4%	-$21.1M-881.0%	-$2.1M-295.9%	-$543K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$0-100.0%	$42.5M-58.8%	$103.0M+275.5%	$27.4M	$0-100.0%	$11.7M+236.7%	$3.5M+630.7%	$476K

CORT Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	98.3%-0.1pp	98.4%-0.3pp	98.7%0.0pp	98.7%+0.1pp	98.6%+0.1pp	98.4%
Operating Margin	5.9%-14.4pp	20.3%-1.9pp	22.2%-5.8pp	28.0%-6.0pp	34.0%-2.2pp	36.2%
Net Margin	13.1%-7.8pp	20.9%-1.1pp	22.0%-3.2pp	25.2%-5.5pp	30.7%+0.8pp	30.0%
Return on Equity	15.4%-5.4pp	20.8%-0.2pp	20.9%+0.7pp	20.2%-9.7pp	29.9%+9.7pp	20.3%
Return on Assets	11.9%-4.9pp	16.8%-0.3pp	17.1%-0.3pp	17.4%-9.2pp	26.6%+8.0pp	18.5%
Current Ratio	2.92-0.4	3.35-1.0	4.39-2.5	6.89+1.3	5.60-4.5	10.07
Debt-to-Equity	0.29+0.1	0.24+0.0	0.23+0.1	0.16+0.0	0.13+0.0	0.09
FCF Margin	18.6%-10.4pp	29.0%+2.8pp	26.2%-3.6pp	29.8%-15.9pp	45.8%+3.2pp	42.6%

Metric	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24	Q1'24
Gross Margin	98.7%+1.0pp	97.8%-0.4pp	98.2%-0.2pp	98.5%+0.1pp	98.4%-0.1pp	98.4%-0.0pp	98.5%+0.2pp	98.3%
Operating Margin	2.2%-2.7pp	4.9%-8.8pp	13.7%+11.5pp	2.2%-11.7pp	13.9%-11.6pp	25.5%+3.8pp	21.7%+1.6pp	20.1%
Net Margin	12.0%+2.5pp	9.5%-8.6pp	18.1%+5.0pp	13.1%-3.8pp	16.9%-9.0pp	25.9%+4.2pp	21.7%+2.8pp	18.9%
Return on Equity	3.8%+0.6pp	3.1%-2.4pp	5.5%+2.5pp	3.0%-1.5pp	4.5%-2.9pp	7.4%+1.4pp	5.9%+0.9pp	5.1%
Return on Assets	2.9%+0.5pp	2.4%-2.0pp	4.4%+1.9pp	2.4%-1.2pp	3.7%-2.4pp	6.0%+1.0pp	5.0%+0.7pp	4.2%
Current Ratio	2.92-0.2	3.14+0.1	3.060.0	3.06-0.3	3.35-0.3	3.70-1.9	5.57+0.4	5.18
Debt-to-Equity	0.29-0.0	0.30+0.0	0.26+0.0	0.240.0	0.240.0	0.23+0.0	0.200.0	0.20
FCF Margin	19.0%-7.2pp	26.2%+3.7pp	22.6%+19.4pp	3.2%-29.8pp	33.0%-6.3pp	39.3%+14.4pp	24.9%+8.7pp	16.2%

Similar Companies

Blueprint Medicines Corp BPMC

$8.4B

Jazz Pharmaceuticals Plc JAZZ

$11.6B

Halozyme Thrp HALO

$7.7B

Verona Pharma VRNA

$9.2B

Revolution Medicines, Inc. RVMD

$19.5B

Frequently Asked Questions

What is Corcept Therapeutics Inc's annual revenue?

Corcept Therapeutics Inc (CORT) reported $761.4M in total revenue for fiscal year 2025. This represents a 12.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Corcept Therapeutics Inc's revenue growing?

Corcept Therapeutics Inc (CORT) revenue grew by 12.8% year-over-year, from $675.0M to $761.4M in fiscal year 2025.

Is Corcept Therapeutics Inc profitable?

Yes, Corcept Therapeutics Inc (CORT) reported a net income of $99.7M in fiscal year 2025, with a net profit margin of 13.1%.

What is Corcept Therapeutics Inc's EBITDA?

Corcept Therapeutics Inc (CORT) had EBITDA of $45.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Corcept Therapeutics Inc's gross margin?

Corcept Therapeutics Inc (CORT) had a gross margin of 98.3% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Corcept Therapeutics Inc's operating margin?

Corcept Therapeutics Inc (CORT) had an operating margin of 5.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Corcept Therapeutics Inc's net profit margin?

Corcept Therapeutics Inc (CORT) had a net profit margin of 13.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Corcept Therapeutics Inc's return on equity (ROE)?

Corcept Therapeutics Inc (CORT) has a return on equity of 15.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Corcept Therapeutics Inc's free cash flow?

Corcept Therapeutics Inc (CORT) generated $141.8M in free cash flow during fiscal year 2025. This represents a -27.7% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Corcept Therapeutics Inc's operating cash flow?

Corcept Therapeutics Inc (CORT) generated $142.0M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Corcept Therapeutics Inc's total assets?

Corcept Therapeutics Inc (CORT) had $836.7M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Corcept Therapeutics Inc's capital expenditures?

Corcept Therapeutics Inc (CORT) invested $211K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Corcept Therapeutics Inc spend on research and development?

Corcept Therapeutics Inc (CORT) invested $254.9M in research and development during fiscal year 2025.

Does Corcept Therapeutics Inc buy back shares?

Yes, Corcept Therapeutics Inc (CORT) spent $172.9M on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

How many shares does Corcept Therapeutics Inc have outstanding?

Corcept Therapeutics Inc (CORT) had 106M shares outstanding as of fiscal year 2025.

What is Corcept Therapeutics Inc's current ratio?

Corcept Therapeutics Inc (CORT) had a current ratio of 2.92 as of fiscal year 2025, which is generally considered healthy.

What is Corcept Therapeutics Inc's debt-to-equity ratio?

Corcept Therapeutics Inc (CORT) had a debt-to-equity ratio of 0.29 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Corcept Therapeutics Inc's return on assets (ROA)?

Corcept Therapeutics Inc (CORT) had a return on assets of 11.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Corcept Therapeutics Inc's Altman Z-Score?

Corcept Therapeutics Inc (CORT) has an Altman Z-Score of 16.98, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Corcept Therapeutics Inc's Piotroski F-Score?

Corcept Therapeutics Inc (CORT) has a Piotroski F-Score of 4 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Corcept Therapeutics Inc's earnings high quality?

Corcept Therapeutics Inc (CORT) has an earnings quality ratio of 1.42x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Corcept Therapeutics Inc?

Corcept Therapeutics Inc (CORT) scores 60 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.